New and recently funded Medical Startups
1
Country: USA | Funding: $15.7M
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
BioEclipse Therapeutics develops targeted immunotherapies against resistant and relapsed solid tumors. Its allogeneic technology harnesses true power of both innate and adaptive immunity for effective treatment. Through its affordable allogeneic (CRX200, IND-ready) and autologous (CRX100, Phase 1b) therapies, BioEclipse has demonstrated the efficacy of targeting the tumor microenvironment of difficult-to-treat solid tumors using living cells programmed to assemble and orchestrate a diverse array of molecules and complex immune pathways. These therapies offer patients the freedom from the apheresis required with each infusion of other cell-based therapies; they also offer more efficient tumor cell killing in a single infusion, reducing the number of infusions and the cell dose and payload.
2
Country: Australia | Funding: A$10M
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
3
Country: UK | Funding: $50M
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
4
Country: UK | Funding: $52M
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
5
Country: USA | Funding: $244.4M
InterVenn Biosciences is a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics. It has combined the molecular resolution of mass spectrometry with the power of artificial intelligence to create a unique platform for discovering new biomarkers, providing more effective treatments, developing precision medicine clinical trials, and identifying new targets. The company has also developed GlcyoKnow Ovarian, a laboratory test for assessing the risk of malignancy in confirmed pelvic lesions prior to planned surgery. It complements imaging data and clinical assessment, facilitating more informed and personalized treatment decisions.
InterVenn Biosciences is a liquid biopsy company pioneering the development of clinically useful glycoproteomic diagnostics. It has combined the molecular resolution of mass spectrometry with the power of artificial intelligence to create a unique platform for discovering new biomarkers, providing more effective treatments, developing precision medicine clinical trials, and identifying new targets. The company has also developed GlcyoKnow Ovarian, a laboratory test for assessing the risk of malignancy in confirmed pelvic lesions prior to planned surgery. It complements imaging data and clinical assessment, facilitating more informed and personalized treatment decisions.
6
Country: Italy | Funding: €1.8M
Soundsafe Care develops robotic device that utilizes ultrasound technology for the treatment of liver cancer. Its focused ultrasound provides a non-invasive and drug-free alternative to radiation therapy, reducing complications and hospitalization costs. Using advanced imaging and automation technologies, the device improves treatment precision and reduces intervention time. The company has developed proprietary software that automates the procedure, making it precise, reproducible and intuitive for the physician. Computer vision and robotics enable tracking and compensation of any potential movement of the therapeutic target, ensuring safety in various surgical settings and anatomical areas. Furthermore, therapy planning and automation speed up the treatment process.
Soundsafe Care develops robotic device that utilizes ultrasound technology for the treatment of liver cancer. Its focused ultrasound provides a non-invasive and drug-free alternative to radiation therapy, reducing complications and hospitalization costs. Using advanced imaging and automation technologies, the device improves treatment precision and reduces intervention time. The company has developed proprietary software that automates the procedure, making it precise, reproducible and intuitive for the physician. Computer vision and robotics enable tracking and compensation of any potential movement of the therapeutic target, ensuring safety in various surgical settings and anatomical areas. Furthermore, therapy planning and automation speed up the treatment process.
7
Country: USA | Funding: $578.8M
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
8
Country: Sweden | Funding: €71.4K
Double Bond Pharmaceutical has developed ways to treat these brain cancer, liver cancer and pneumonia much more effectively with its drug delivery system.
Double Bond Pharmaceutical has developed ways to treat these brain cancer, liver cancer and pneumonia much more effectively with its drug delivery system.
9
Country: Germany | Funding: $40K
TheraBionic manufactures FDA-cleared device TheraBionic P1 for the treatment of advanced hepatocellular carcinoma, with or without metastasis. It emits low-frequency radiofrequency electromagnetic fields that inhibit tumor cell growth without affecting normal cell growth. In clinical trials, TheraBionic's tumor-specific radiofrequency has been shown to be effective in shrinking tumors, blocking the growth of new cancer cells and increasing overall survival. The device is compact and easy to use. In multiple studies, patients treated with the device did not experience the debilitating side effects associated with other cancer treatments. The TheraBionic P1 is also being evaluated for the treatment of metastatic pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
TheraBionic manufactures FDA-cleared device TheraBionic P1 for the treatment of advanced hepatocellular carcinoma, with or without metastasis. It emits low-frequency radiofrequency electromagnetic fields that inhibit tumor cell growth without affecting normal cell growth. In clinical trials, TheraBionic's tumor-specific radiofrequency has been shown to be effective in shrinking tumors, blocking the growth of new cancer cells and increasing overall survival. The device is compact and easy to use. In multiple studies, patients treated with the device did not experience the debilitating side effects associated with other cancer treatments. The TheraBionic P1 is also being evaluated for the treatment of metastatic pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
10
Country: USA | Funding: $272.5M
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
Senti Bio is developing a new generation of cell and gene therapies for cancer patients. The company has created the Gene Circuit Technology Platform to create gene circuits that can be integrated into new drugs with increased precision. These gene circuits allow to precisely destroy cancer cells, spare healthy cells, increase target tissue specificity and/or provide control even after drug administration. Clinical and preclinical studies have demonstrated the efficacy of the identified gene circuits, which target both NK cells and T cells, allowing the company to select the right cell type for each indication. The company's portfolio includes cell therapies targeting difficult-to-treat myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors.
